<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04669951</url>
  </required_header>
  <id_info>
    <org_study_id>uPAR ECV</org_study_id>
    <nct_id>NCT04669951</nct_id>
  </id_info>
  <brief_title>Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer</brief_title>
  <official_title>Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Adenocarcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Patrick Achiam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate urokinase Plasminogen Activator Receptor (uPAR)&#xD;
      microexpression in gastroesophageal cancer (adenocarcinomas) both qualitatively and&#xD;
      semi-quantitatively and to evaluate if it offers a possibility for future imagining purposes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Sections of the tumor tissue will be HE stained.&#xD;
&#xD;
        -  Sections of the tumor tissue will be stained with an uPAR antibody for&#xD;
           immunohistochemistry.&#xD;
&#xD;
        -  Immunohistochemical staining against cytokeratin which colors cancer cells will be made&#xD;
           to assist the observer in the evaluation of uPAR microexpression pattern.&#xD;
&#xD;
        -  A semiqualitative scale corresponding to the level of uPAR expression will be made.&#xD;
&#xD;
        -  Quantitative polymerase chain reaction will be used to validate the immunohistochemistry&#xD;
           uPAR expression pattern.&#xD;
&#xD;
        -  An electronic scoring system (digital pathology) will be trained to access the&#xD;
           expression of uPAR in both tumor- and normal tissue.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Actual">November 30, 2020</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The patients will be drawn from the existing clinical biobank. The biobank is located at the department of pathology, Rigshospitalet. From this clinical biobank, a new temporary research biobank will be made. Supplementary sections from formalin-fixed paraffin embedded (FFPE) blocks containing tumor tissue will be cut and Haematoxylin and eosin (HE) and immunohistochemical (IHC) staining will be performed.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>uPAR microexpression</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Our primary objective is to investigate uPAR microexpression in gastroesophageal adenocarcinomas both qualitatively and semi-quantitatively. This will be done by a pathology analysis of gastroesophageal cancer resections.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor-to-background ratio</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>A pathology staining will determine the uPAR in the tumor compared with the healthy cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>uPAR in patient groups</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Baseline statistical analysis of patient groups and their expression of uPAR in their resected tumor tissues will be made.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Esophagus Cancer, Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>uPAR expression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunohistochemistry</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>uPAR immunohistochemistry</intervention_name>
    <description>Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression</description>
    <arm_group_label>uPAR expression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥18 years old.&#xD;
&#xD;
          -  Patients who underwent curatively intended surgery for gastroesophageal cancer&#xD;
&#xD;
          -  Patients who underwent surgery after 01-01-2016.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who applied for an exception from medical research at the &quot;National Registry&#xD;
             of Tissue Use.&quot;&#xD;
&#xD;
          -  Patients with other histological subtypes than adenocarcinoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Achiam, MD., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Department of Surgical Gastroenterology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>Region Hovedstaden</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Michael Patrick Achiam</investigator_full_name>
    <investigator_title>Consultant, MD, DMSci, Ph.D., FEBS-OG, Ass. Professor</investigator_title>
  </responsible_party>
  <keyword>urokinase plasminogen activator receptor</keyword>
  <keyword>uPAR</keyword>
  <keyword>Cardia</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Immunohistochemistry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

